Oric Pharmaceuticals Ownership

ORIC Stock  USD 11.80  0.65  5.83%   
The majority of Oric Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Oric Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Oric Pharmaceuticals. Please pay attention to any change in the institutional holdings of Oric Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
2019-03-31
Previous Quarter
70.7 M
Current Value
71 M
Avarage Shares Outstanding
42.2 M
Quarterly Volatility
17.6 M
 
Covid
Some institutional investors establish a significant position in stocks such as Oric Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Oric Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

Oric Stock Ownership Analysis

About 92.0% of the company shares are owned by institutional investors. The book value of Oric Pharmaceuticals was now reported as 3.09. The company recorded a loss per share of 1.9. Oric Pharmaceuticals had not issued any dividends in recent years. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Oric Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. To find out more about Oric Pharmaceuticals contact MD MBA at 650 388 5600 or learn more at https://www.oricpharma.com.
Besides selling stocks to institutional investors, Oric Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Oric Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Oric Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Oric Pharmaceuticals Quarterly Liabilities And Stockholders Equity

242.86 Million

Oric Pharmaceuticals Insider Trades History

About 8.0% of Oric Pharmaceuticals are currently held by insiders. Unlike Oric Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Oric Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Oric Pharmaceuticals' insider trades
 
Covid

Oric Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Oric Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oric Pharmaceuticals backward and forwards among themselves. Oric Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oric Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
State Street Corp2025-03-31
2.2 M
Nea Management Company, Llc2025-03-31
2.2 M
Vivo Capital, Llc2025-03-31
2.1 M
Silverarc Capital Management, Llc2025-03-31
2.1 M
First Turn Management Llc2025-03-31
M
Balyasny Asset Management Llc2025-03-31
M
Commodore Capital Lp2025-03-31
M
Boxer Capital Management, Llc2025-03-31
1.7 M
Mpm Oncology Impact Management Lp2025-03-31
1.4 M
Viking Global Investors Lp2025-03-31
6.6 M
Blackrock Inc2025-03-31
5.4 M
Note, although Oric Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Oric Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oric Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oric Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oric Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Piscitelli Dominic over three weeks ago
Disposition of 20000 shares by Piscitelli Dominic of Oric Pharmaceuticals at 10.0486 subject to Rule 16b-3
 
Piscitelli Dominic over a month ago
Disposition of 300 shares by Piscitelli Dominic of Oric Pharmaceuticals at 10.0 subject to Rule 16b-3
 
Chacko Jacob over a month ago
Acquisition by Chacko Jacob of 16666 shares of Oric Pharmaceuticals subject to Rule 16b-3
 
Chacko Jacob over three months ago
Acquisition by Chacko Jacob of 600000 shares of Oric Pharmaceuticals at 8.26 subject to Rule 16b-3
 
Kunkel Lori Anne over three months ago
Acquisition by Kunkel Lori Anne of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3
 
Chacko Jacob over six months ago
Acquisition by Chacko Jacob of 100000 shares of Oric Pharmaceuticals subject to Rule 16b-3
 
Chacko Jacob over six months ago
Acquisition by Chacko Jacob of 100000 shares of Oric Pharmaceuticals subject to Rule 16b-3
 
Chacko Jacob over six months ago
Acquisition by Chacko Jacob of 300000 shares of Oric Pharmaceuticals at 4.36 subject to Rule 16b-3
 
Chacko Jacob over six months ago
Disposition of 24660 shares by Chacko Jacob of Oric Pharmaceuticals at 8.2812 subject to Rule 16b-3
 
Chacko Jacob over six months ago
Disposition of 16667 shares by Chacko Jacob of Oric Pharmaceuticals subject to Rule 16b-3
 
Multani Pratik S over six months ago
Disposition of 2089 shares by Multani Pratik S of Oric Pharmaceuticals at 3.25 subject to Rule 16b-3
 
Richard Heyman over six months ago
Acquisition by Richard Heyman of 53700 shares of Oric Pharmaceuticals subject to Rule 16b-3

Oric Pharmaceuticals Outstanding Bonds

Oric Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oric Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oric bonds can be classified according to their maturity, which is the date when Oric Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Oric Pharmaceuticals Corporate Filings

17th of July 2025
Other Reports
ViewVerify
F4
2nd of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
24th of June 2025
Other Reports
ViewVerify
8K
13th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.90)
Return On Assets
(0.31)
Return On Equity
(0.48)
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.